Group 1 - The company has introduced professional managers to assist in reform and optimize product structure, leading to improved profitability. The company, established in 1997, has a diverse product matrix in functional sugars and nutritional supplements, consisting of five layers: starch sugars, reduced-sugar sweeteners, prebiotics, dietary fibers, and special functional food ingredients. After the peak and subsequent decline of erythritol in 2019, the company adjusted its operational strategies and product structure during the industry downturn, resulting in a significant rebound in profits and gross margin improvement last year [1] - Erythritol is benefiting from anti-dumping measures, and there is a focus on the domestic market potential for allulose. Following the surge in popularity of erythritol in 2021, prices have stabilized at a low point due to new production capacities. The company has an annual capacity of 30,000 tons and is the domestic enterprise with the lowest anti-dumping tax rate in the EU, which is expected to lead to a rise in both volume and price in the European market. The optimal marginal pricing for the company in Europe is estimated at 15,800 yuan per ton, higher than the domestic price of 6,500 yuan per ton. Additionally, the U.S. has initiated a "double anti" investigation against Chinese erythritol, with preliminary anti-dumping tax rates set at 260%-450%. The company is not a mandatory respondent, and attention should be paid to the market changes in the U.S. following the May tax rate announcement. Allulose, as a new star in the sugar substitute market, has significant growth potential, with domestic approval expected in March [1][2] Group 2 - In 2024, all major segments of the company achieved growth in both sales and gross margin, with stock incentives reflecting confidence in future development. The company reported a net profit attributable to shareholders of 111 million yuan in 2024, a year-on-year increase of 106%. The growth was driven by increased sales and gross margins across key revenue segments, with sales volumes for prebiotics, dietary fibers, reduced-sugar sweeteners, starch sugars, and others reaching 357,000 tons, 214,000 tons, 500,000 tons, and 2,426,000 tons, respectively, representing year-on-year growth of 23.74%, 14.39%, 41.66%, and 2.29%. Gross margins for these segments were 24.60%, 18.12%, 9.09%, and 12.22%, with year-on-year increases of 5.26 percentage points, 5.48 percentage points, 7.83 percentage points, and 2.17 percentage points. The company announced stock incentives for 2024, with performance targets for 2025-2027 set at 170 million yuan, 212 million yuan, and 265 million yuan, corresponding to growth rates of 53%, 25%, and 25%, demonstrating confidence in future development [2] Group 3 - Profit forecasts and valuations indicate that the company is expected to achieve net profits attributable to shareholders of 181 million yuan, 216 million yuan, and 260 million yuan from 2025 to 2027, with corresponding PE valuations of 20.07, 16.82, and 13.99 times. The initial coverage has been initiated with a "buy" rating [3]

山东三元生物科技股份有限公司 证券简称：三元生物 年度业绩说明会投资者关系活动记录表 编号：2025-001 | | □ □媒体采访 √业绩说明会 特 | | --- | --- | | 投资者关系活动 | | | | 定 □ | | 类别 | 对 新 | | | □ 象 闻 | | | 现 调 | | | 发 □ 场 | | | 研 布 其 | | | 参 □ | | 参 | 会 他 | | | 观 采用网络远程方式进行，面向全体投资者 分 | | 及人员姓名 与 | □路演活动 ： | | | □电话会议 析 （请文字说明其他活动内容） | | 单 | 师 | | 时间 | 2 会 | | 位 | 议 | | 地点 | 0 深 | | 名 | | | | 2 圳 | | 称 | 主持人：三元生物 | | | 5 证 | | | 董事长：聂在建 | | | 年 券 | | | 总经理：程保华 | | 公司接待人员 | 月 交 | | | 董秘：高亮 | | 姓名 | 日 易 | | | 财务总监：于俊玲 | | | 所 | | | 独立董事：谭海宁 | | | " | | | 保荐代表人：陆丹君 | | | ...

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [1] Core Views - The company reported a revenue of 1.152 billion yuan for 2024, representing a year-on-year increase of 32.64%. The net profit attributable to shareholders was 246 million yuan, up 27.26% year-on-year [4][6] - The company has successfully launched new production capacities, which, along with increasing downstream demand, has significantly supported revenue and profit growth [6][7] - The D-alloheptulose product is expected to be approved for market entry, which could drive additional revenue growth for the company [8][10] - The company is expanding its production capacity in Thailand, which is anticipated to lower production costs and enhance profitability [9][10] Summary by Sections Financial Performance - In Q4 2024, the company achieved a revenue of 331 million yuan, a year-on-year increase of 54.46% and a quarter-on-quarter increase of 14.61%. The net profit attributable to shareholders was 63 million yuan, up 21.97% year-on-year [4] - For Q1 2025, the company reported a revenue of 313 million yuan, a year-on-year increase of 24.27%, while the net profit attributable to shareholders was 81 million yuan, up 52.06% year-on-year [5] Production Capacity and Sales - The company successfully launched projects for 30,000 tons of dietary fiber, 10,000 tons of crystalline fructose, and 5,000 tons of D-alloheptulose, which have contributed to increased sales and revenue [7] - The main products, including prebiotics, dietary fibers, and healthy sweeteners, generated revenues of 322 million, 624 million, and 156 million yuan respectively, with year-on-year growth rates of 25.43%, 40.42%, and 13.85% [6] Market and Policy Environment - The company is well-positioned to benefit from favorable policies aimed at promoting healthy consumption, which aligns with its diverse product offerings [10] - The anticipated approval of D-alloheptulose as a new food ingredient is expected to significantly boost domestic demand and revenue [8][10] Future Projections - The company forecasts net profits attributable to shareholders of 338 million, 412 million, and 537 million yuan for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 20, 16, and 13 [11]

证券之星消息，2025年4月30日保龄宝（002286）发布公告称公司于2025年4月29日召开分析师会议，浙 商证券（601878）石化分析师邹骏程、方正证券食品饮料分析师谌保罗、华泰柏瑞基金管理有限公司丁 续、大成基金管理有限公司刘芳琳、摩根基金管理(中国)有限公司刘健、交银施罗德基金管理有限公司 张明晓、路博迈基金管理(中国)有限公司谢楠、海富通基金管理有限公司踪敬珍、西部利得基金管理有 限公司张昭君陈雨、中邮创业基金管理股份有限公司綦征、嘉合基金管理有限公司曹瀚允、国泰海通证 券基础化工分析师周志鹏、招商基金于凡真、金信基金管理有限公司龙毅、宁波盛世知己投资管理中心 (有限合伙)王小刚、安信证券资产管理有限公司王炳修、杭州巨子私募基金管理有限公司张立烽、湖南 源乘私募基金管理有限公司邬安沙、武汉证国私募陈阜东、中债信用增进投资股份有限公司郑倩、 PleiadInvestmentAdvisorsLimited孫洋、上海云门投资管理有限公司俞忠华、信达证券（601059）食品饮 料分析师赵雷、上海途灵资产管理有限公司赵梓峰、华安证券（600909）化工新材料分析师刘天其、中 信建投（601066）证券食品 ...

| 上市公司接 | 总经理 王强 | | --- | --- | | 待人员姓名 | 董事会秘书 朱哲 | | | 财务总监 周瑜 | | | 董事会秘书首先向与会机构代表介绍公司基本情况及 2024 年年度和 2025 | | | 年一季度经营情况。 | | | 公司主要从事益生元、膳食纤维、减糖甜味剂等功能性配料的研发、生产、 | | | 销售，系国内功能糖首家产业化生产企业和上市公司，致力于成为全球功能配料 | | | 与健康食品创新的引领者。公司布局食品营养、口感和质构改善以及医药原辅料 | | | 三大业务领域。食品营养领域主要产品为益生元、膳食纤维、减糖甜味剂等，口 | | | 感和质构改善领域主要以变性淀粉为主，医药原辅料领域主要为药用乳果糖、药 | | | 用赤藓糖醇等。 | | | 公司已形成淀粉、淀粉糖、减糖甜味剂、膳食纤维、益生元、药用糖（醇） | | | 等的全产业链制造体系和自下而上附加值逐步提升的产品金字塔矩阵，可满足下 | | | 游客户"多品种、差异化、全方位"采购需求。 | | 投资者关系 | 2024 年度，公司实现归属于上市公司股东的净利润 11,115.98 万元，同比 ...

阿洛酮糖内需释放可期。随着25 年3 月国家卫健委公告将D-阿洛酮糖作为新食品原料的申请纳入公开 征求意见范围，我们认为，阿洛酮糖在国内获批在即，或有望在今年上半年正式获批。《健康中国行 动》将功能性代糖纳入重点支持目录，2025 年专项补贴超5 亿元，以满足慢性病防控的"饮食干预"刚 需，为阿洛酮糖等代糖产品的发展提供了政策支持。 盈利预测：我们预计公司2025-27 年可实现归母净利润3.41/4.57/6.24亿元，同比分别 +39%/+34%/+37%，当前股价对应2025-27 年PE 分别为20X/15X/11X，维持"强烈推荐"评级。 风险提示：项目投产进度不及预期；技术快速迭代、市场竞争加剧；原材料价格大幅波动；产能消化不 及预期；全球关税波动风险等 25Q1 分产品看：25Q1 公司膳食纤维系列实现收入1.70 亿元，同比+25.4%，益生元系列实现收入0.86 亿元，同比+17.3%，健康甜味剂系列实现收入0.50 亿元，同比+105.3%，其他淀粉糖（醇）实现收入 0.02 亿元，同比+10.3%。我们判断，25Q1 公司受益于产能释放，各类产品收入均有所增长，尤其阿洛 酮糖产品增长明显 ...

Group 1 - The core viewpoint of the articles highlights that Baolingbao Biotech Co., Ltd. reported a revenue of 2.402 billion yuan in 2024, a year-on-year decline of 4.84%, while net profit surged by 105.97% to 111 million yuan, and non-recurring net profit increased by 254.56% to 124 million yuan [2] - The significant profit growth is attributed to the increase in sales of high-value-added products and effective cost control, with core businesses such as prebiotics, dietary fiber, and sugar-reducing sweeteners experiencing revenue growth of 16.02%, 14.52%, and 29.73% respectively [2] - Sales revenue of erythritol saw a remarkable increase of 52.58%, primarily due to the implementation of the EU anti-dumping policy, allowing Baolingbao to capture the European market with a minimum tax rate of 34.4% [2] Group 2 - Research and development innovation is another highlight for Baolingbao, with R&D expenditure rising to 4.08% of revenue and the R&D team expanding to 154 members, with a significant increase in the proportion of highly educated talent [3] - In March 2025, Baolingbao won the iSEE Global Innovation Award for its "high-purity breast milk oligosaccharide Shumuzi" technology, reinforcing its technological leadership in the functional sugar sector [3] - However, the company faces challenges such as fluctuations in raw material prices and intensified industry competition, particularly with a 31.98% year-on-year decline in revenue from the feed and by-products business, which has negatively impacted overall income [3] - Looking ahead, Baolingbao plans to intensify its expansion efforts in the European and American markets and advance its functional sugar alcohol project in the United States to enhance global competitiveness [3]